Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
166
datasets available to search
ShareScore release 0.9.0
Dataset results
166 results for “CDK4/6 inhibitors”
The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER+ breast cancer with mitotic aberrations
<p>This study aims to investigate the accumulation of genomic instability and chromosome segregation errors after the acquisition of resistance to CDK4/6i in ER+ breast cancer and to test the efficacy of mitotic kinase inhibitors as a potential treatment for CDK4/6i-resistant breast cancer patients.</p> <p><strong>This repository contains whole-exome and shallow whole-genome sequencing from luminal breast cancer cell lines (T47D, LY2, MDA-MB-361, CAMA1, MCF7, KPL1, ZR751, HCC1428) both at the untreated or Parental state and post resistance to Palbociclib.</strong></p> <p>Palbociclib resistance was developed by continuous dose-escalation of palbociclib up to 0.5-1 μM until cell growth was observed in the presence of the drug (6-8 months for cell lines). During this time, parental cell lines and organoids were cultured in regular media to match the time spent in culture. Once resistance was established, Palbo-R cell lines were cultured in a regular growth medium without palbociclib. Cells were cultured without palbociclib for at least two weeks before evaluating resistance.</p>
Data from: Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
Using an ORF kinome screen in MCF-7 cells treated with the CDK4/6 inhibitor ribociclib plus fulvestrant, we identified FGFR1 as a mechanism of drug resistance. FGFR1-amplified/ER+ breast cancer cells and MCF-7 cells transduced with FGFR1 were resistant to fulvestrant ± ribociclib or palbociclib. This resistance was abrogated by treatment with the FGFR tyrosine kinase inhibitor (TKI) lucitanib. Addition of the FGFR TKI erdafitinib to palbociclib/fulvestrant induced complete responses of FGFR1-amplified/ER+ patient-derived-xenografts. Next generation sequencing of circulating tumor DNA (ctDNA) in 34 patients after progression on CDK4/6 inhibitors identified FGFR1/2 amplification or activating mutations in 14/34 (41%) post-progression specimens. Finally, ctDNA from patients enrolled in MONALEESA-2, the registration trial of ribociclib, showed that patients with FGFR1 amplification exhibited a shorter progression-free survival compared to patients with wild type FGFR1. Thus, we propose breast cancers with FGFR pathway alterations should be considered for trials using combinations of ER, CDK4/6 and FGFR antagonists.
A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy
ClinicalTrials.gov study NCT02607124. IPD Sharing: Not stated. Countries: 1. Publications: 2.
A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenop
ClinicalTrials.gov study NCT01684215. IPD Sharing: YES. Countries: 1. Publications: 3.
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC
ClinicalTrials.gov study NCT03041311. IPD Sharing: NO. Countries: 7. Publications: 6.
Data from: Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
Open the record for dataset details and reuse information.
CDK4/6 inhibitors display a class effect in inducing differentiation of neuroblastoma cells
<p><span>Underlying and Extended data for the manuscript: "</span>CDK4/6 inhibitors display a class effect in inducing differentiation of neuroblastoma cells", Ferguson <em>et al </em>(2024). Includes Underlying Data for Figures 1A-D, Figures 2A-F and Figures 3A-D and the Extended Data: Supplementary Information, data for Figures S1A-C and Movies S1 and S2.</p>
Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study
ClinicalTrials.gov study NCT05586841. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.
ClinicalTrials.gov study NCT07227233. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study to Learn About How Medicines Called CDK4/6 Inhibitors Are Used in People With Advanced or Metastatic Breast Cancer in Australia
ClinicalTrials.gov study NCT06624020. IPD Sharing: NO. Countries: 1. Publications: 0.
Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial
ClinicalTrials.gov study NCT04486911. IPD Sharing: YES. Countries: 1. Publications: 1.
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
ClinicalTrials.gov study NCT04964934. IPD Sharing: YES. Countries: 23. Publications: 2.
Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor
ClinicalTrials.gov study NCT05181033. IPD Sharing: NO. Countries: 1. Publications: 14.
To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer
ClinicalTrials.gov study NCT04660435. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
ClinicalTrials.gov study NCT07214532. IPD Sharing: NO. Countries: 0. Publications: 10.
Biomarkers and Clinical Features of Metastatic Breast Cancer in Patients Treated With CDK4/6 Inhibitors
ClinicalTrials.gov study NCT04526587. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer
ClinicalTrials.gov study NCT05112536. IPD Sharing: NO. Countries: 1. Publications: 0.
Prognostic Impact of the Neutrophil/Lymphocyte Ratio (NLR) in the Treatment of First-line Metastatic or Locally Advanced Breast Cancer Treated With CDK4/6 Inhibitor.
ClinicalTrials.gov study NCT05303129. IPD Sharing: NO. Countries: 1. Publications: 0.
Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas
ClinicalTrials.gov study NCT05580588. IPD Sharing: NO. Countries: 1. Publications: 0.
A Real-life Study to Learn About the Use and Effects of the CDK4/6 Inhibitors in Canadian Patients With Breast Cancer.
ClinicalTrials.gov study NCT05770713. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.